Adapting isotonic dose-finding to a dynamic set of drug combinations with application to a phase I leukemia trial

Abstract

Background/aims

This article describes the proposed design of a phase I study evaluating the safety of ceramide nanoliposome and vinblastine among an initial set of 19 possible dose combinations in patients with relapsed/refractory acute myeloid leukemia and patients with untreated acute myeloid leukemia who are not candidates for intensive induction chemotherapy.

Methods

Extensive collaboration between statisticians and clinical investigators revealed the need to incorporate several adaptive features into the design, including the flexibility of adding or eliminating certain dose combinations based on safety criteria applied to multiple dose pairs. During the design stage, additional dose levels of vinblastine were added, increasing the dimension of the drug combination space and thus the complexity of the problem. Increased complexity made application of existing drug combination dose-finding methods unsuitable in their current form.

Results

Our solution to these challenges was to adapt a method based on isotonic regression to meet the research objectives of the study. Application of this adapted method is described herein, and a simulation study of the design’s operating characteristics is conducted.

Conclusion

The aim of this article is to bring to light examples of novel design applications as a means of augmenting the implementation of innovative designs in the future and to demonstrate the flexibility of adaptive designs in satisfying changing design conditions.

Keywords

Dose-finding phase I drug combination

Get full access to this article

View all access options for this article.

References

Braun

Wang

. A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents. Biometrics 2010; 66(3): 805–812.

Yin

Yuan

. Bayesian dose finding in oncology for drug combinations by copula regression. J Royal Stat Soc Ser C Appl Stat 2009; 58: 211–224.

Wages

Conaway

O’Quigley

. Continual reassessment method for partial ordering. Biometrics 2011; 67(4): 1555–1563.

Melssen

Petroni

Chianese-Bullock

, et al. A multipeptide vaccine plus toll-like receptor agonists or polyICLC in combination with incomplete freund’s adjuvant in melanoma patients. J Immunother Cancer 2019; 7: 163.

Wages

Slingluff

Jr Petroni

. A phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies. Contemp Clin Trials 2015; 41: 172–179.

Wages

Millard

Dillon

, et al. Efficient dose-finding for drug combination studies involving a shift in study populations. Contemp Clin Trials Commun 2020; 17: 100519.

Ivanova

Wang

. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials. Stat Med 2004; 23: 1861–1870.

Gandhi

Bahleda

Tolaney

, et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 2014; 32: 68–75.

Conaway

Dunbar

Peddada

. Designs for single- or multiple-agent phase I trials. Biometrics 2004; 60: 661–669.

10.

Jones

Moskaluk

Gillenwater

, et al. Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer. J Thorac Oncol 2012; 7(11): 1683–1690.

11.

Lee

Cheung

. Model calibration in the continual reassessment method. Clin Trials 2009; 6(3): 227–238.

12.

Barlow

Bartholomew

Bremner

, et al. Statistical inference under order restrictions: the theory and application of isotonic regression. New York: Wiley, 1972.

13.

Hirakawa

Wages

Sato

, et al. A comparative study of adaptive dose-finding design for phase I oncology trials of combination therapies. Stat Med 2015; 34: 3194–3213.

14.

Wages

Ivanova

Marchenko

. Practical designs for phase I combination studies I oncology. J Biopharm Stat 2016; 26: 150–166.

15.

Conaway

Wages

. Designs for phase I trials in ordered groups. Stat Med 2017; 36: 254–265.

16.

Conaway

. A design for phase I trials in completely or partially ordered groups. Stat Med 2017; 36: 2323–2332.

17.

Conaway

. Isotonic designs for phase I trials in partially ordered groups. Clin Trials 2017; 14(5): 491–498.

18.

Robertson

Wright

Dykstra

. Order restricted statistical inference. New York: John Wiley & Sons, 1988.

19.

Hwang

Peddada

. Confidence interval estimation subject to order restrictions. Ann Stat 1994; 22: 67–93.

20.

Cheung

. Coherence principles in dose finding studies. Biometrika 2005; 92: 863–873.

21.

Yuan

Nguyen

Thall

. Bayesian designs for phase I-II clinical trials. New York: CRC Press, 2016.

22.

Wages

Conaway

. Revisiting isotonic phase I design in the era of model-assisted dose-finding. Clin Trials 2018; 15(5): 524–529.

23.

Cheung

. On the use of nonparametric curves in phase I trials with low toxicity tolerance. Biometrics 2002; 58(1): 237–240.

24.

Cheung

. Dose finding by the continual reassessment method. New York: CRC Press, 2011.

25.

Riviere

Le Tourneau

Paoletti

, et al. Designs of drug-combination phase I trials in oncology: a systematic review of the literature. Ann Oncol 2015; 26(4): 669–674.

26.

Paoletti

Ezzalfani

Le Tourneau

. Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials. Ann Oncol 2015; 26(9): 1808–1812.

27.

Iasonos

O’Quigley

. Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol 2014; 32: 2505–2511.

28.

Nie

Rubin

Mehrotra

, et al. Rendering the 3+3 design to rest: more efficient approaches to oncology dose-finding trials in the era of targeted therapy. Clin Cancer Res 2016; 22: 2623–2629.

29.

R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2008.

30.

Iasonos

Gönen

Bosl

. Scientific review of phase I protocols with novel dose-escalation designs: how much information is needed? J Clin Oncol 2015; 33: 2221–2225.

31.

Petroni

Wages

Paux

, et al. Implementation of adaptive methods in early-phase clinical trials. Stat Med 2017; 36: 215–224.

32.

Wages

Conaway

Slingluff

Jr , et al. Recent developments in the implementation of novel designs for early-phase combination studies. Ann Oncol 2015; 26(5): 1036–1037.

33.

Conaway

Petroni

. The impact of early phase trial design in the drug development process. Clin Cancer Res 2019; 25: 819–827.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.53 MB